Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by Asset Management One Co. Ltd.

Asset Management One Co. Ltd. lessened its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 3.8% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 65,363 shares of the biopharmaceutical company's stock after selling 2,590 shares during the quarter. Asset Management One Co. Ltd. owned 0.05% of Alnylam Pharmaceuticals worth $15,554,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Creative Planning boosted its position in Alnylam Pharmaceuticals by 24.6% in the third quarter. Creative Planning now owns 10,012 shares of the biopharmaceutical company's stock valued at $2,754,000 after buying an additional 1,978 shares during the last quarter. Bleakley Financial Group LLC lifted its stake in Alnylam Pharmaceuticals by 24.7% during the 3rd quarter. Bleakley Financial Group LLC now owns 2,215 shares of the biopharmaceutical company's stock valued at $609,000 after acquiring an additional 439 shares during the period. Blue Trust Inc. boosted its holdings in shares of Alnylam Pharmaceuticals by 431.0% in the 3rd quarter. Blue Trust Inc. now owns 462 shares of the biopharmaceutical company's stock valued at $127,000 after acquiring an additional 375 shares during the last quarter. Friedenthal Financial acquired a new stake in shares of Alnylam Pharmaceuticals in the third quarter worth $51,000. Finally, Essex LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the third quarter worth $217,000. 92.97% of the stock is owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Price Performance

ALNY stock traded up $0.51 during midday trading on Wednesday, reaching $250.51. The stock had a trading volume of 740,941 shares, compared to its average volume of 693,172. The company's fifty day simple moving average is $253.96 and its 200 day simple moving average is $263.29. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27. The company has a market cap of $32.43 billion, a price-to-earnings ratio of -115.44 and a beta of 0.35. Alnylam Pharmaceuticals, Inc. has a 52-week low of $141.98 and a 52-week high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing analysts' consensus estimates of ($0.62) by ($0.03). As a group, sell-side analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.94 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. Wolfe Research lowered shares of Alnylam Pharmaceuticals from a "peer perform" rating to an "underperform" rating in a report on Tuesday, November 12th. Chardan Capital reissued a "buy" rating and issued a $300.00 price objective on shares of Alnylam Pharmaceuticals in a report on Friday, November 1st. William Blair reaffirmed an "outperform" rating on shares of Alnylam Pharmaceuticals in a report on Tuesday, November 19th. Canaccord Genuity Group lifted their price target on Alnylam Pharmaceuticals from $384.00 to $385.00 and gave the company a "buy" rating in a research report on Tuesday. Finally, Sanford C. Bernstein lowered their price objective on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an "outperform" rating on the stock in a research report on Tuesday, January 7th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and nineteen have assigned a buy rating to the stock. According to data from MarketBeat.com, Alnylam Pharmaceuticals currently has an average rating of "Moderate Buy" and an average price target of $299.48.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 5,219 shares of the firm's stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total value of $1,309,864.62. Following the completion of the sale, the chief executive officer now directly owns 78,880 shares of the company's stock, valued at $19,797,302.40. This trade represents a 6.21 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Tolga Tanguler sold 1,469 shares of the firm's stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total value of $368,689.62. Following the completion of the sale, the executive vice president now directly owns 13,191 shares of the company's stock, valued at $3,310,677.18. This trade represents a 10.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 81,356 shares of company stock worth $22,498,551. Corporate insiders own 1.50% of the company's stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.